Phaseline

Companies › Vima Therapeutics

Vima Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VIM0423
Combination product containing VMA-1001 and VMA-1002
–Phase 2Dystonia; PARKINSON DISEASE (Disorder)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07304089VIM0423Phase 2DystoniaNeurologyMar 2027
NCT07804615VIM0423Phase 2PARKINSON DISEASE (Disorder)NeurologyJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.